Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 62.24% is in line with its 5-year average of 57.85%, around the middle of its 5-year range (47.20%–83.58%).
1.14% above its 12-month average of 61.54%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 66.81%.
GROSS MARGIN
62.24%
GROSS MARGIN AVG TTM
61.54%
GROSS MARGIN AVG 3Y
62.38%
GROSS MARGIN AVG 5Y
57.85%
GROSS MARGIN AVG 10Y
70.86%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+1.14%
CURRENT VS 3Y AVG
-0.23%
CURRENT VS 5Y AVG
+7.59%
CURRENT VS 10Y AVG
-12.17%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.44%
median of 787 covered companies
CURRENT VS SECTOR MEDIAN
+53.91%
vs the sector median at left
Journey Medical Corporation
Market Cap
$176.55M
Gross Margin
62.24%
TTM Avg
61.54%
3Y Avg
62.38%
5Y Avg
57.85%
Market Cap
$176.97M
Gross Margin
97.51%
TTM Avg
97.98%
3Y Avg
98.99%
5Y Avg
98.22%
Market Cap
$176.31M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
25.00%
5Y Avg
16.67%
Market Cap
$173.23M
Gross Margin
83.01%
TTM Avg
91.50%
3Y Avg
95.75%
5Y Avg
97.17%
Market Cap
$172.81M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$172.53M
Gross Margin
99.69%
TTM Avg
100.00%
3Y Avg
-73.48%
5Y Avg
-190.92%
Market Cap
$182.12M
Gross Margin
0.65%
TTM Avg
0.33%
3Y Avg
50.16%
5Y Avg
60.13%
Market Cap
$170.49M
Gross Margin
67.59%
TTM Avg
75.78%
3Y Avg
75.92%
5Y Avg
75.58%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Journey Medical Corporation (DERM) | $176.55M | 62.24% | 61.54% | 62.38% | 57.85% |
| Yarrow Bioscience Inc (YARW)vs › | $176.97M | 97.51% | 97.98% | 98.99% | 98.22% |
| Compass Therapeutics, Inc. (CMPX)vs › | $176.31M | 0.00% | 50.00% | 25.00% | 16.67% |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.23M | 83.01% | 91.50% | 95.75% | 97.17% |
| Precision BioSciences, Inc. (DTIL)vs › | $172.81M | 100.00% | 100.00% | 100.00% | 100.00% |
| Cue Biopharma, Inc. (CUE)vs › | $172.53M | 99.69% | 100.00% | -73.48% | -190.92% |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $182.12M | 0.65% | 0.33% | 50.16% | 60.13% |
| Organogenesis Holdings Inc. (ORGO)vs › | $170.49M | 67.59% | 75.78% | 75.92% | 75.58% |
| MediWound Ltd. (MDWD)vs › | $169.76M | 15.46% | 16.11% | 25.27% | 28.77% |
| Nkarta, Inc. (NKTX)vs › | $169.56M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
62.2%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 66.81% |
| 2026-03-31 | 53.99% |
| 2025-12-31 | 59.54% |
| 2025-09-30 | 67.36% |
| 2025-06-30 | 60.00% |
| 2025-03-31 | 55.44% |
| 2024-12-31 | 83.58% |
| 2024-09-30 | 63.87% |
| 2024-06-30 | 55.97% |
| 2024-03-31 | 47.69% |
| 2023-12-31 | 60.58% |
| 2023-09-30 | 81.39% |
| 2023-06-30 | 54.77% |
| 2023-03-31 | 47.20% |
| 2022-12-31 | 51.66% |
| 2022-09-30 | 55.19% |
| 2022-06-30 | 58.27% |
| 2022-03-31 | 64.79% |
| 2021-12-31 | 58.75% |
| 2021-09-30 | 58.35% |
| 2021-06-30 | 58.90% |
| 2021-03-31 | 63.54% |
| 2020-12-31 | 68.80% |
| 2020-09-30 | 64.23% |
| 2020-06-30 | 66.82% |
| 2020-03-31 | 67.54% |
| 2019-09-30 | 83.25% |
| 2019-06-30 | 98.00% |
| 2019-03-31 | 62.23% |
| 2018-12-31 | 58.14% |
| 2018-09-30 | 66.95% |
| 2018-06-30 | 100.00% |
| 2018-03-31 | 100.00% |
| 2017-12-31 | 100.00% |
| 2017-09-30 | 100.00% |
| 2017-06-30 | 100.00% |
| 2017-03-31 | 100.00% |
| 2016-12-31 | 100.00% |
| 2016-09-30 | 100.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 100.00% |
| 2015-09-30 | 100.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 100.00% |
